These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37950437)

  • 1. Treatment of epidermolysis bullosa simplex with dupilumab.
    Sun X; Zhang J; Yang Q; Lin J
    J Dermatol; 2024 Apr; 51(4):e131-e132. PubMed ID: 37950437
    [No Abstract]   [Full Text] [Related]  

  • 2. Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
    Yang DY; Jing WW; Liu X; Li L; Lu T; Li XL
    Adv Skin Wound Care; 2024 Feb; 37(2):1-4. PubMed ID: 38241457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.
    Shao L; Zhong DQ; Liu YM; Wang JQ
    Int J Dermatol; 2023 Oct; 62(10):e542-e545. PubMed ID: 37326291
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab.
    Caroppo F; Milan E; Giulioni E; Belloni Fortina A
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e365-e367. PubMed ID: 34927769
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient.
    Xará J; Relvas M; Figueiredo C; Calvão J; Batista M; Ramos L
    Int J Dermatol; 2023 Dec; 62(12):e617-e618. PubMed ID: 37622659
    [No Abstract]   [Full Text] [Related]  

  • 6. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report.
    Wang Y; Zhou M; Zhang L; Zheng S; Hong Y; Gao XH
    Dermatol Ther; 2021 Nov; 34(6):e15130. PubMed ID: 34528352
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.
    Shehadeh W; Sarig O; Bar J; Sprecher E; Samuelov L
    Br J Dermatol; 2020 Jun; 182(6):1495-1497. PubMed ID: 31899820
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab.
    Roque Quintana B; Piqué Durán E; Pérez Cejudo JA
    Actas Dermosifiliogr; 2024 Feb; 115(2):184-186. PubMed ID: 36871818
    [No Abstract]   [Full Text] [Related]  

  • 9. Experience of dupilumab treatment in inherited epidermolysis bullosa: A short series.
    Bellon N; Bataille P; Bonigen J; Charbit-Henrion F; Dietrich C; Polivka L; Hadj-Rabia S; Leite de Moraes M; Bodemer C
    J Am Acad Dermatol; 2024 Aug; 91(2):373-376. PubMed ID: 38679237
    [No Abstract]   [Full Text] [Related]  

  • 10. Are existing validated severity scores for epidermolysis bullosa reflective of the burden of disease in patients with epidermolysis bullosa simplex?
    Hunjan MK; Bardhan A; Zuzarte L; Balacco DL; Harper N; Heagerty A
    Clin Exp Dermatol; 2023 Jun; 48(6):706-707. PubMed ID: 36972307
    [No Abstract]   [Full Text] [Related]  

  • 11. Advanced gene-editing strategy for epidermolysis bullosa simplex.
    Sheriff A; Jacków-Malinowska J
    Mol Ther; 2024 Feb; 32(2):271-272. PubMed ID: 38266650
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidermolysis bullosa simplex of the hands and the feet; a genetic study of the hereditary type.
    JOHNSON SA; TEST AR
    Arch Derm Syphilol; 1946 Jun; 53():610-9. PubMed ID: 20987148
    [No Abstract]   [Full Text] [Related]  

  • 13. EPIDERMOLYSIS BULLOSA SIMPLEX IN TASMANIA.
    TILSLEY DA; BEARD TC
    Lancet; 1963 Nov; 2(7314):905-7. PubMed ID: 14052060
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel mutation in the helix termination peptide of keratin 5 causing epidermolysis bullosa simplex Dowling-Meara.
    Irvine AD; McKenna KE; Bingham A; Nevin NC; Hughes AE
    J Invest Dermatol; 1997 Dec; 109(6):815-6. PubMed ID: 9406827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case of inherited epidermolysis bullosa simplex with KLHL24 gene mutation in Japan.
    Miyake T; Natsuga K; Umayahara T; Naito S; Yoshimoto J; Senoo A; Wang HT; Hsu CK; Yamasaki O; Morizane S
    J Dermatol; 2022 Jan; 49(1):e24-e25. PubMed ID: 34658058
    [No Abstract]   [Full Text] [Related]  

  • 16. Perioperative Management of Congenital Epidermolysis Bullosa.
    Yukawa H; Makino T; Hayashi K; Date H; Honda N; Anami Y
    Ann Thorac Surg; 2023 Jul; 116(1):e1-e4. PubMed ID: 35863401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa.
    Gewert S; Davidovic M; Has C; Kiritsi D
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1139-1144. PubMed ID: 38679781
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapies for epidermolysis bullosa: delivery is key.
    Bremer J; van den Akker PC
    Br J Dermatol; 2019 Jan; 180(1):17-19. PubMed ID: 30604552
    [No Abstract]   [Full Text] [Related]  

  • 19. A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: two identical de novo mutations.
    Koss-Harnes D; Høyheim B; Anton-Lamprecht I; Gjesti A; Jørgensen RS; Jahnsen FL; Olaisen B; Wiche G; Gedde-Dahl T
    J Invest Dermatol; 2002 Jan; 118(1):87-93. PubMed ID: 11851880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermolysis bullosa in Northern Ireland.
    McKenna KE; Walsh MY; Bingham EA
    Br J Dermatol; 1992 Oct; 127(4):318-21. PubMed ID: 1419751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.